- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 844442-38-2] AT7519
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-50940 |
| Brand: | MCE |
| CAS: | 844442-38-2 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 382.24 |
| Molecular Formula | C16H17Cl2N5O2 |
| SMILES | O=C(NC1=CNN=C1C(NC2CCNCC2)=O)C3=C(Cl)C=CC=C3Cl |
7 Publications Citing Use of MCE
Summary
IC50 & Target
|
CDK9/Cyclin T 10 nM (IC 50 ) |
CDK5/p35 13 nM (IC 50 ) |
cdk2/cyclin A 47 nM (IC 50 ) |
Cdk4/cyclin D1 100 nM (IC 50 ) |
cdk6/cyclin D3 170 nM (IC 50 ) |
||
|
Cdk1/cyclin B 210 nM (IC 50 ) |
CDK7/Cyclin H/MAT1 2400 nM (IC 50 ) |
GSK3β 89 nM (IC 50 ) |
||||
In Vitro
AT7519 (0-4 μM) results in dose-dependent cytotoxicity with IC 50 s ranging from 0.5 to 2 μM in MM cells, and this induced cytotoxicity is associated with GSK-3β activation independent of transcriptional inhibition. AT7519 overcomes proliferative advantage conferred by cytokines and the protective effect of BMSC. AT7519 (0.5 μM) induces apoptosis of MM cells in a time-dependent manner. Moreover, AT7519 (0.5 μM) inhibits phosphorylation of RNA polymerase II CTD and partially inhibits RNA synthesis in MM.1S cells [1] . AT7519 (250 nM) inhibits cell cycle progression in human tumor cell lines. AT7519 also induces apoptosis of human tumor cell lines [2] . AT7519 (100-700 nM) induces apoptosis in leukemia cell lines. AT7519 also inhibits transcription in human tumor cell lines. Furthermore, AT7519 inhibits RNA polymerase II and reduces antiapoptotic protein levels [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
AT7519 inhibits tumor growth in a human MM xenograft mouse model [1] . AT7519 (4.6 and 9.1 mg/kg/dose) inhibits the growth of early-stage HCT116 tumor xenografts. AT7519 (10 mg/kg, i.p.) also inhibits the target CDKs in HCT116 tumor-bearing BALB/c nude mice [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01183949 | Astex Pharmaceuticals, Inc.|Multiple Myeloma Research Consortium |
Multiple Myeloma
|
November 2010 | Phase 1|Phase 2 |
| NCT00390117 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific
|
August 22, 2006 | Phase 1 |
| NCT01652144 | NCIC Clinical Trials Group|Astex Pharmaceuticals, Inc.|Canadian Cancer Trials Group |
Mantle Cell Lymphoma
|
July 24, 2012 | Phase 2 |
| NCT01627054 | NCIC Clinical Trials Group|Astex Pharmaceuticals, Inc.|Canadian Cancer Trials Group |
Chronic Lymphocytic Leukemia
|
June 21, 2012 | Phase 2 |
| NCT02503709 | National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Unresectable Solid Neoplasm
|
April 8, 2016 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 50 mg/mL ( 130.81 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.6162 mL | 13.0808 mL | 26.1616 mL |
| 5 mM | 0.5232 mL | 2.6162 mL | 5.2323 mL |
| 10 mM | 0.2616 mL | 1.3081 mL | 2.6162 mL |
References
- [1] Santo L, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22;29(16):2325-36.
- [2] Squires MS, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
- [3] Squires MS, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther. 2010 Apr;9(4):920-8.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.